ArticleHepatology (Baltimore, Md.)2022
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis.
Article in Hepatology (Baltimore, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Aspirin in Patients with Viral Hepatitis: Systematic Review and Meta-Analysis of Observational Studies.Journal of gastrointestinal cancer · 2024Pooled it
- Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.Alimentary pharmacology & therapeutics · 2023Pooled it
- 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.Clinical and molecular hepatology · 2022Guideline
- KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA).Clinical and molecular hepatology · 2026Article
- Aspirin for hepatocellular carcinoma prevention in MASLD: How far are we ready to proceed?: Editorial on "Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis".Clinical and molecular hepatology · 2026Article
- Correspondence to editorial 1 on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis".Clinical and molecular hepatology · 2026Article
- Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis.Clinical and molecular hepatology · 2026Article
- Aspirin reduces short-term mortality risk in critically ill patients with liver cirrhosis: a propensity-score matched retrospective analysis using the MIMIC-IV database.BMC gastroenterology · 2025Article
- Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study.Annals of medicine · 2025Article
- Genetic insights into the interaction between chronic hepatitis B virus infection and metabolic syndrome.Virulence · 2025Article
- Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis.Journal of gastroenterology and hepatology · 2025Article
- Long-term use of low-dose aspirin for cancer prevention: A 20-year longitudinal cohort study of 1,506,525 Hong Kong residents.International journal of cancer · 2025Article
- Association between aspirin use and the risk of incident nonalcoholic fatty liver disease.European journal of epidemiology · 2025Article
- Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks.Life (Basel, Switzerland) · 2024Review
- Effect of Low-Dose Aspirin Use After Thermal Ablation in Patients with Hepatocellular Carcinoma: A Retrospective Study.Journal of hepatocellular carcinoma · 2024Article
- Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea.Infectious diseases and therapy · 2023Article
- The Effect of Aspirin Use on Incident Hepatocellular Carcinoma-An Updated Systematic Review and Meta-Analysis.Cancers · 2023Review
- Impact of Aspirin Use on Outcomes in Patients With Hepatocellular Cancer: A Nationwide Analysis.World journal of oncology · 2023Article
- May an aspirin a day truly take hepatocellular carcinoma away?Annals of translational medicine · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsStudies on differential effect of aspirin therapy on HCC risk across the spectrum of liver diseases are lacking. We investigated the association between aspirin use and risks of HCC, liver-associated death, and major bleeding in chronic hepatitis B (CHB) patients with or without cirrhosis. APPROACH AND
resultsWe identified 329,635 eligible adults with CHB from 2007 through 2017, using the Korean National Health Insurance Service database, including patients who received aspirin for ≥90 consecutive days (n = 20,200) and patients who never received antiplatelet therapy (n = 309,435). Risks of HCC, liver-associated mortality, and major bleeding were estimated in a propensity-score-matched cohort (19,003 pairs), accounting for competing risks. With a median follow-up of 6.7 years, 10-year cumulative incidence of HCC was 9.5% in the aspirin-treated group and 11.3% in the untreated group (adjusted subdistribution hazard ratio [aSHR], 0.85; 95% CI, 0.78-0.92). However, among patients with cirrhosis (2479 pairs), an association of aspirin use with HCC risk was not evident (aSHR, 1.00; 95% CI, 0.85-1.18). Cirrhosis status had a significant effect on the association between aspirin use and HCC risk (p
conclusionsAspirin use was associated with reduced risks of HCC and liver-associated mortality in adults with CHB. Cirrhosis status had a substantial effect on the association between aspirin use and HCC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.